CFHR3 and hepatocellular carcinoma: Furthermore, we are the first to indicate that CFHR3 can act as a diagnostic serum biomarker to distinguish Patients with HCC from healthy controls and is an effective target to block the stimulatory effects of hypoxia on HCC cells.